Medication info
J Gabapentin Capsule 150 mg (Pregabalin)

J Gabapentin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
A white hard capsule containing a white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 202000751 · Approved 2020.02.10 · Insurance code 645406500

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not secondary generalized symptoms are present. Additionally, it helps alleviate the symptoms of fibromyalgia. It is utilized for managing various neurological disorders and pain, thereby improving the quality of life for patients.

How to take

Adult dose

This medication is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at a starting dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors. Therefore, if symptoms of depression or mood changes occur during treatment, please inform your healthcare provider immediately. Individuals allergic to any component of this medication or with certain genetic disorders such as lactose intolerance should not take this drug. Patients with diabetes should be cautious, as weight gain may require adjustment of blood sugar control medications. If symptoms of angioedema occur, discontinue use immediately and consult a physician. Elderly patients should be careful due to the risk of injury caused by dizziness or drowsiness, especially during the early stages of treatment. Transient visual disturbances or changes in vision may occur. If these symptoms manifest, consult a physician. Suddenly stopping this medication may lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety. Therefore, it should be tapered gradually according to a physician's instructions. Patients with a history of substance abuse are at a higher risk of abusing this medication, requiring special attention during administration. Cardiac disease or severe congestive heart failure patients should use this medication with caution, and those with respiratory diseases or kidney disorders may require dose adjustment. When taken with opioid analgesics, the central nervous system depressant effects may be enhanced. During early pregnancy, there may be a risk of fetal malformations, so the medication should not be taken during pregnancy. Women of childbearing age should employ effective contraception. Breastfeeding women should avoid using this medication as it may transfer to breast milk and affect the infant. Care should be taken when engaging in hazardous activities such as driving or operating machinery due to the potential for dizziness or drowsiness. If severe skin rash or allergic symptoms occur, discontinue use immediately and consult a healthcare provider. When storing this medication, keep it out of reach of children and do not transfer it to other containers.

Side effects

  • suicidal impulses
  • suicidal behaviors
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 195 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • derealization
  • sexual sensation disorders
  • restlessness
  • agitation
  • mood swings
  • emotional drop
  • emotional rise
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • indifference
  • ataxia
  • motor coordination disorders
  • balance disorders
  • memory loss
  • attention deficit
  • memory impairment
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonic jerks
  • reflex reduction
  • motor abnormalities
  • psychomotor agitation
  • position-related dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • fainting
  • confusion
  • decreased motor activity
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • blurred vision
  • double vision
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • conjunctival swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness in the visual field
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive saliva secretion
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • difficulty swallowing
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is recommended to maintain a storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A white hard capsule containing a white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.